Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose ticagrelor versus standard antiplatelet regimens in high-risk Chinese patients after PCI
ChiCTR1900024834Phase 4Recruiting
- Sponsor
- Fuwai Central China Cardiovascular Hospital
- Start
- May 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ticagrelor, aspirin and clopidogrel in acute coronary syndrome (ACS) and coronary arteriosclerosis (3 arms), sponsored by Fuwai Central China Cardiovascular Hospital. Primary endpoints: Cardiac troponin I/T, Creatine kinase-MB and 6 more. Started May 2019; status: recruiting.
02
Drugs
ticagreloraspirinclopidogrel
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1900024834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024834.